Introduction/Background Molecular classification of endometrial cancer (EC) has entered clinical use and possess prognostic information in early stages. We sought to identify a clinical prognostic score for advanced EC.

Methodology A total of 114 EC patients were analyzed in this multicenter retrospective study. All patients included in the study underwent chemotherapy. A Weibull multiple regression model was adopted to evaluate the combined impact of clinical data on overall survival (OS) and to obtain a prognostic score. Each variables is allotted a ’partial score’ that depends on the size of the regression coefficient. Total scores can range between 0 and 6.1 and assign patients to three different risk groups according to a 36-months survival probability: group 1, >70%; group 2, 30%-70%; and group 3, <30%. We estimated OS probabilities by the exponential model and by the Kaplan-Meier method.

Results In multivariate analysis grade, ECOG performance status (PS), platelets count and time from surgery to the start of 1st line chemotherapy were predictive for OS and PFS. By applying the FaTE score, three risk groups were identified: group 1 (47.4% of patients) with a score of ≤1.0, group 2 (30.7%) with a score of 1.1–2.4 and group 3 (21.9%) with a score of ≥2.5. Median OS (mOS) was significantly different among the three risk groups: risk group 1, mOS not reached (nr); risk group 2, 42.1 months (95%CI 24.1-nr) and risk group 3, 11.5 months (95%CI 7.4–28.6), p<0.0001. 36-months survival probability was 88% (95% CI, 78–98) for risk group 1, 56% (95% CI, 37–75) for risk group 2 and 28% (95% CI, 9–47) for risk group 3. The c-index score was 0.839 (95%CI 0.745 – 0.932).

Conclusion This analysis demonstrated that this easy-to-use tool, at no additional costs, provides accurate prognostic stratification for EC. Validation of our FaTE score is warranted.

Disclosures A.F. has received personal honoraria for lectures from Astrazeneca, GSK-Tesaro, Clovis, and advisory board from Jannsen, Astrazeneca, GSK-Tesaro.